Form 4: Cartesian Therapeutics Director Timothy Springer Increases Stake in RNAC

Director Timothy Springer reports purchasing additional shares of Cartesian Therapeutics (RNAC) between December 19 and December 23, 2024, increasing his total holdings.

Summary

• Timothy Springer, a director and 10% owner of Cartesian Therapeutics, Inc. (RNAC), has reported several transactions involving the purchase of common stock.
• Between December 19 and December 23, 2024, Springer acquired a total of 42,189 shares through multiple transactions at prices ranging from $16.81 to $19.00 per share.
• These purchases increased Springer's direct holdings to 8,507,895 shares.
• Springer also has indirect ownership through his wife (330,695 shares) and TAS Partners LLC (529,798 shares).
• Following these transactions, Springer's total beneficial ownership, including direct and indirect holdings, is substantial.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed as a positive sign, but the document itself is simply a report of transactions.

Positives

• A director's purchase of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider buying is often monitored as an indicator of management's and directors' sentiment about the company's prospects, relative to the broader market and industry trends.

Key Dates